Cantor Fitzgerald Issues Negative Outlook for RARE Earnings

Key Points

• Cantor Fitzgerald has revised its FY2025 earnings per share estimate for Ultragenyx Pharmaceutical to ($5.19), slightly lower than its previous estimate of ($5.15), maintaining an "Overweight" rating with a target price of $105.00.
• Recent analyst reports show mixed opinions, with HC Wainwright upgrading the stock to "buy" at $80.00, while Morgan Stanley reduced their target from $65.00 to $55.00.
• Ultragenyx reported a quarterly EPS of ($1.17), which surpassed the consensus estimate of ($1.27), alongside a revenue increase of 13.2% year-over-year, totaling $166.5 million.

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) - Analysts at Cantor Fitzgerald dropped their FY2025 EPS estimates for Ultragenyx Pharmaceutical in a research report issued on Wednesday, August 6th. Cantor Fitzgerald analyst K. Kluska now expects that the biopharmaceutical company will post earnings of ($5.19) per share for the year, down from their previous forecast of ($5.15). Cantor Fitzgerald currently has a "Overweight" rating and a $105.00 target price on the stock. The consensus estimate for Ultragenyx Pharmaceutical's current full-year earnings is ($5.18) per share. Cantor Fitzgerald also issued estimates for Ultragenyx Pharmaceutical's FY2026 earnings at ($3.21) EPS.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported ($1.17) EPS for the quarter, topping the consensus estimate of ($1.27) by $0.10. The firm had revenue of $166.50 million during the quarter, compared to analyst estimates of $161.37 million. Ultragenyx Pharmaceutical had a negative net margin of 87.34% and a negative return on equity of 237.48%. Ultragenyx Pharmaceutical's revenue for the quarter was up 13.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($1.52) earnings per share.

Other equities analysts have also issued research reports about the stock. Morgan Stanley reduced their price objective on shares of Ultragenyx Pharmaceutical from $65.00 to $55.00 and set an "overweight" rating for the company in a research report on Monday, July 14th. Wells Fargo & Company reduced their price target on shares of Ultragenyx Pharmaceutical from $88.00 to $65.00 and set an "overweight" rating for the company in a research report on Thursday, July 10th. HC Wainwright raised shares of Ultragenyx Pharmaceutical to a "buy" rating and set a $80.00 price objective on the stock in a research report on Monday, July 28th. William Blair assumed coverage on Ultragenyx Pharmaceutical in a report on Wednesday, May 28th. They set an "outperform" rating and a $65.00 price target on the stock. Finally, Canaccord Genuity Group lowered their price target on Ultragenyx Pharmaceutical from $136.00 to $128.00 and set a "buy" rating on the stock in a report on Friday. One analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $81.50.

Ultragenyx Pharmaceutical Stock Down 1.0%

Shares of RARE stock traded down $0.29 during trading hours on Friday, reaching $27.54. The stock had a trading volume of 1,527,932 shares, compared to its average volume of 2,607,080. Ultragenyx Pharmaceutical has a twelve month low of $25.81 and a twelve month high of $60.37. The firm has a 50-day simple moving average of $33.32 and a 200-day simple moving average of $36.68.

Insider Transactions at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, Director Corazon (Corsee) D. Sanders sold 2,405 shares of the business's stock in a transaction on Friday, June 20th. The stock was sold at an average price of $37.39, for a total value of $89,922.95. Following the transaction, the director owned 15,344 shares of the company's stock, valued at approximately $573,712.16. The trade was a 13.55% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 5.50% of the company's stock.

Institutional Trading of Ultragenyx Pharmaceutical

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Price T Rowe Associates Inc. MD increased its position in shares of Ultragenyx Pharmaceutical by 28.1% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,218,942 shares of the biopharmaceutical company's stock valued at $116,559,000 after purchasing an additional 706,519 shares during the last quarter. Adage Capital Partners GP L.L.C. lifted its holdings in Ultragenyx Pharmaceutical by 81.6% in the 1st quarter. Adage Capital Partners GP L.L.C. now owns 2,149,000 shares of the biopharmaceutical company's stock worth $77,815,000 after buying an additional 965,919 shares during the period. Federated Hermes Inc. lifted its holdings in Ultragenyx Pharmaceutical by 0.3% in the 1st quarter. Federated Hermes Inc. now owns 2,055,200 shares of the biopharmaceutical company's stock worth $74,419,000 after buying an additional 5,400 shares during the period. Geode Capital Management LLC lifted its stake in shares of Ultragenyx Pharmaceutical by 4.0% in the 2nd quarter. Geode Capital Management LLC now owns 1,712,931 shares of the biopharmaceutical company's stock valued at $62,291,000 after purchasing an additional 66,394 shares during the period. Finally, Deutsche Bank AG increased its position in Ultragenyx Pharmaceutical by 0.5% during the 1st quarter. Deutsche Bank AG now owns 1,701,493 shares of the biopharmaceutical company's stock valued at $61,611,000 after buying an additional 8,385 shares in the last quarter. 97.67% of the stock is currently owned by institutional investors.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.